Bessemer Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bessemer Group’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$231M	Sell	1,805,630 -47,602	-3%	-$5.94M	0.36%	59
2025 Q4	$226M	Buy	1,853,232 +220,244	+13%	+$25.3M	0.35%	61
2025 Q3	$164M	Buy	1,632,988 +138,322	+9%	+$12.5M	0.25%	104
2025 Q2	$124M	Buy	1,494,666 +62,600	+4%	+$4.99M	0.2%	127
2025 Q1	$116M	Buy	1,432,066 +55,232	+4%	+$4.94M	0.21%	124
2024 Q4	$124M	Buy	1,376,834 +73,866	+6%	+$7.16M	0.2%	123
2024 Q3	$129M	Buy	1,302,968 +204,981	+19%	+$20.1M	0.21%	127
2024 Q2	$102M	Buy	1,097,987 +175,116	+19%	+$15.7M	0.18%	138
2024 Q1	$87.6M	Buy	922,871 +15,794	+2%	+$1.47M	0.16%	156
2023 Q4	$81M	Buy	907,077 +422,112	+87%	+$31.3M	0.16%	168
2023 Q3	$35.4M	Sell	484,965 -234,050	-33%	-$18.7M	0.08%	200
2023 Q2	$59.8M	Buy	719,015 +32,646	+5%	+$2.73M	0.13%	176
2023 Q1	$52.3M	Buy	686,369 +19,576	+3%	+$1.62M	0.12%	178
2022 Q4	$55.3M	Buy	666,793 +176,031	+36%	+$14.3M	0.13%	167
2022 Q3	$38.9M	Buy	490,762 +490,142	+79,055%	+$41.3M	0.1%	183
2022 Q2	$46K	Sell	620 -260	-30%	-$19.5K	﹤0.01%	1114
2022 Q1	$79K	Sell	880 -283	-24%	-$26.1K	﹤0.01%	1008
2021 Q4	$130K	Hold	1,163	–	–	﹤0.01%	945
2021 Q3	$146K	Hold	1,163	–	–	﹤0.01%	854
2021 Q2	$157K	Sell	1,163 -264	-19%	-$34.7K	﹤0.01%	843
2021 Q1	$193K	Buy	1,427 +182	+15%	+$27.2K	﹤0.01%	757
2020 Q4	$175K	Buy	1,245 +573	+85%	+$73.4K	﹤0.01%	755
2020 Q3	$75K	Hold	672	–	–	﹤0.01%	887
2020 Q2	$75K	Hold	672	–	–	﹤0.01%	1281
2020 Q1	$52K	Hold	672	–	–	﹤0.01%	1219
2019 Q4	$64K	Hold	672	–	–	﹤0.01%	1244
2019 Q3	$51K	Hold	672	–	–	﹤0.01%	1269
2019 Q2	$59K	Hold	672	–	–	﹤0.01%	1285
2019 Q1	$61K	Hold	672	–	–	﹤0.01%	1248
2018 Q4	$48K	Hold	672	–	–	﹤0.01%	1332
2018 Q3	$64K	Hold	672	–	–	﹤0.01%	1225
2018 Q2	$64K	Hold	672	–	–	﹤0.01%	1204
2018 Q1	$59K	Hold	672	–	–	﹤0.01%	1215
2017 Q4	$57K	Hold	672	–	–	﹤0.01%	1238
2017 Q3	$58K	Hold	672	–	–	﹤0.01%	1279
2017 Q2	$52K	Hold	672	–	–	﹤0.01%	1288
2017 Q1	$47K	Hold	672	–	–	﹤0.01%	1314
2016 Q4	$40K	Buy	672 +246	+58%	+$15.2K	﹤0.01%	1397
2016 Q3	$28K	Hold	426	–	–	﹤0.01%	1305
2016 Q2	$23K	Hold	426	–	–	﹤0.01%	975
2016 Q1	$22K	Hold	426	–	–	﹤0.01%	1047
2015 Q4	$30K	Buy	+426	New	+$29.1K	﹤0.01%	1061
2013 Q4	–	Sell	-165	Closed	-$7K	–	1399
2013 Q3	$7K	Hold	165	–	–	﹤0.01%	1082
2013 Q2	$6K	Buy	+165	New	+$5.8K	﹤0.01%	1123

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bessemer Group's XBI Position: Q1 2026 in Review

Bessemer Group reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 2.6% in Q1 2026, selling an estimated $5.94M and leaving 1,805,630 shares worth $231M. The position accounts for 0.36% of the portfolio, ranked #59.

Bessemer Group first reported a position in XBI in Q2 2013 and has held it in 44 quarters since. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Bessemer Group held 1,805,630 shares of State Street SPDR S&P Biotech ETF worth $231M as of Q1 2026.
Bessemer Group sold 47,602 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $5.94M.
State Street SPDR S&P Biotech ETF made up 0.36% of Bessemer Group's portfolio in Q1 2026, its #59 holding.
Bessemer Group first reported a position in State Street SPDR S&P Biotech ETF in Q2 2013 and has held it in 44 quarters since.
813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Bessemer Group's 13F filing for Q1 2026, filed 6 May 2026.